SPC Financial Inc. Acquires 2,061 Shares of Merck & Co., Inc. (NYSE:MRK)

SPC Financial Inc. boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 6.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,272 shares of the company’s stock after purchasing an additional 2,061 shares during the period. SPC Financial Inc.’s holdings in Merck & Co., Inc. were worth $2,958,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Gantzert Investment Co. LLC ADV purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $2,373,000. Buckingham Capital Management Inc. raised its stake in shares of Merck & Co., Inc. by 4.8% during the 4th quarter. Buckingham Capital Management Inc. now owns 69,479 shares of the company’s stock worth $5,309,000 after buying an additional 3,177 shares in the last quarter. Nations Financial Group Inc. IA ADV raised its stake in shares of Merck & Co., Inc. by 3.5% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,318 shares of the company’s stock worth $1,018,000 after buying an additional 446 shares in the last quarter. Mcmillion Capital Management Inc. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $3,074,000. Finally, Corient Capital Partners LLC raised its stake in shares of Merck & Co., Inc. by 25.7% during the 4th quarter. Corient Capital Partners LLC now owns 27,769 shares of the company’s stock worth $2,122,000 after buying an additional 5,682 shares in the last quarter. 75.34% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on the company. Bank of America set a $97.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, July 11th. ValuEngine downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Argus increased their target price on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. UBS Group increased their target price on Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Finally, Morgan Stanley increased their target price on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, June 21st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $92.56.



NYSE MRK traded up $1.39 during mid-day trading on Friday, hitting $84.85. The stock had a trading volume of 3,704,667 shares, compared to its average volume of 9,473,462. Merck & Co., Inc. has a 52-week low of $66.10 and a 52-week high of $87.07. The company has a market cap of $220.40 billion, a price-to-earnings ratio of 19.55, a P/E/G ratio of 1.75 and a beta of 0.56. The company has a 50 day simple moving average of $83.36 and a 200 day simple moving average of $80.92. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same period last year, the business posted $1.06 EPS. Merck & Co., Inc.’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, equities analysts anticipate that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.59%. The ex-dividend date of this dividend is Friday, September 13th. Merck & Co., Inc.’s payout ratio is currently 50.69%.

In related news, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total value of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total value of $18,514,218.74. Following the completion of the transaction, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Market Timing – The Benefits and the Danger

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.